Type 2 diabetes, thiazolidinediones, and cardiovascular risk

By Taylor Clare   Hobbs FD Richard  

British Journal of General Practice, Vol. 59, Iss. 564, 2009-07 ,pp. : 520-524

Royal College of General Practitioners

Access to resources Recommend Favorite

Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population‐based retrospective cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 309-318

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long‐term type 2 diabetes: A cross‐sectional survey in China

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Introduction: the role of the thiazolidinediones in the cardiovascular risk management of type 2 diabetes

By Barnett A.H.  

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 1-4

Informa Healthcare

Access to resources Recommend Favorite

Early insulin therapy and the risk of cardiovascular disease in Type 2 diabetes

By Nicasio John   McFarlane Samy I  

Therapy, Vol. 2, Iss. 5, 2005-09 ,pp. : 685-688

Future Medicine

Access to resources Recommend Favorite